ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Calcitrol+Docetaxel Prolongs Survival In Prostate Cancer

June 24, 2005

In Congress: Continuing Resolutions Keep Feds Running; Henney Nomination Stalled By Nickles

October 16, 1998

Interim Results Show Vaccine Lowers Breast Cancer Recurrence

December 30, 2011

NCI Publishes Report On Pancreatic Cancer

March 7, 2014

In Brief: NCI’s Katz Named Director, Arthritis Institute; Hayden Promoted At Bristol-Myers Squibb

July 14, 1995

Sixty CCOPs Could cost $16 Million; DCPC Staff Believes They Can Get It

October 10, 1986